Immunic Statistics
Share Statistics
Immunic has 90.08M shares outstanding. The number of shares has increased by 99.53% in one year.
| Shares Outstanding | 90.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 87.36M |
| Failed to Deliver (FTD) Shares | 6.08K |
| FTD / Avg. Volume | 0.66% |
Short Selling Information
The latest short interest is 4.50M, so 4.99% of the outstanding shares have been sold short.
| Short Interest | 4.50M |
| Short % of Shares Out | 4.99% |
| Short % of Float | 5.15% |
| Short Ratio (days to cover) | 4.66 |
Valuation Ratios
The PE ratio is -0.71 and the forward PE ratio is -1.8.
| PE Ratio | -0.71 |
| Forward PE | -1.8 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 2.3 |
| P/FCF Ratio | -0.93 |
| PEG Ratio | n/a |
Enterprise Valuation
Immunic Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 0.
| Current Ratio | 2.12 |
| Quick Ratio | 2.12 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -3.24% and return on capital (ROIC) is -327.85%.
| Return on Equity (ROE) | -3.24% |
| Return on Assets (ROA) | -1.72% |
| Return on Capital (ROIC) | -327.85% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.10M |
| Employee Count | 85 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -24.67% in the last 52 weeks. The beta is 1.88, so Immunic 's price volatility has been higher than the market average.
| Beta | 1.88 |
| 52-Week Price Change | -24.67% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 1.33 |
| Relative Strength Index (RSI) | 42.62 |
| Average Volume (20 Days) | 920.16K |
Income Statement
In the last 12 months, Immunic had revenue of $0 and earned -$93.61M in profits. Earnings per share was $-2.11.
| Revenue | 0 |
| Gross Profit | -111.00K |
| Operating Income | -99.22M |
| Net Income | -93.61M |
| EBITDA | -99.11M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.11 |
Balance Sheet
The company has $46.67M in cash and $1.33M in debt, giving a net cash position of $45.34M.
| Cash & Cash Equivalents | 46.67M |
| Total Debt | 1.33M |
| Net Cash | 45.34M |
| Retained Earnings | -410.89M |
| Total Assets | 64.76M |
| Working Capital | 39.91M |
Cash Flow
In the last 12 months, operating cash flow was -$70.83M and capital expenditures -$334.00K, giving a free cash flow of -$71.16M.
| Operating Cash Flow | -70.83M |
| Capital Expenditures | -334.00K |
| Free Cash Flow | -71.16M |
| FCF Per Share | -1.61 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
IMUX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -186.73% |
| FCF Yield | -69.91% |
Analyst Forecast
The average price target for IMUX is $10, which is 785% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 785% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Apr 15, 2019. It was a backward split with a ratio of 1:40.
| Last Split Date | Apr 15, 2019 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -12.06 |
| Piotroski F-Score | 1 |